1
|
Freitas NFQR, Otaka DY, Galvão CC, de Almeida DM, Ferreira MRA, Moreira Júnior C, Hidalgo MMMH, Conceição FR, Salvarani FM. Humoral Immune Response Evaluation in Horses Vaccinated with Recombinant Clostridium perfringens Toxoids Alpha and Beta for 12 Months. Toxins (Basel) 2021; 13:566. [PMID: 34437437 PMCID: PMC8402361 DOI: 10.3390/toxins13080566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 07/16/2021] [Accepted: 07/19/2021] [Indexed: 11/23/2022] Open
Abstract
In horses, Clostridium perfringens is associated with acute and fatal enterocolitis, which is caused by a beta toxin (CPB), and myonecrosis, which is caused by an alpha toxin (CPA). Although the most effective way to prevent these diseases is through vaccination, specific clostridial vaccines for horses against C. perfringens are not widely available. The aim of this study was to pioneer the immunization of horses with three different concentrations (100, 200 and 400 µg) of C. perfringens recombinant alpha (rCPA) and beta (rCPB) proteins, as well as to evaluate the humoral immune response over 360 days. Recombinant toxoids were developed and applied to 50 horses on days 0 and 30. Those vaccines attempted to stimulate the production of alpha antitoxin (anti-CPA) and beta antitoxin (anti-CPB), in addition to becoming innocuous, stable and sterile. There was a reduction in the level of neutralizing anti-CPA and anti-CPB antibodies following the 60th day; therefore, the concentrations of 200 and 400 µg capable of inducing a detectable humoral immune response were not determined until day 180. In practical terms, 200 µg is possibly the ideal concentration for use in the veterinary industry's production of vaccines against the action of C. perfringens in equine species.
Collapse
Affiliation(s)
- Nayra F. Q. R. Freitas
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| | - Denis Y. Otaka
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| | - Cleideanny C. Galvão
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| | - Dayane M. de Almeida
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| | - Marcos R. A. Ferreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul CEP 96160-000, Brazil; (M.R.A.F.); (C.M.J.); (F.R.C.)
| | - Clóvis Moreira Júnior
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul CEP 96160-000, Brazil; (M.R.A.F.); (C.M.J.); (F.R.C.)
| | - Marina M. M. H. Hidalgo
- Faculdade de Veterinária, Universidade Federal de Pelotas, Rio Grande do Sul CEP 96160-000, Brazil;
| | - Fabricio R. Conceição
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul CEP 96160-000, Brazil; (M.R.A.F.); (C.M.J.); (F.R.C.)
| | - Felipe M. Salvarani
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| |
Collapse
|
2
|
Moreira C, Ferreira MRA, Finger PF, Magalhães CG, Cunha CEP, Rodrigues RR, Otaka DY, Galvão CC, Salvarani FM, Moreira ÂN, Conceição FR. Protective efficacy of recombinant bacterin vaccine against botulism in cattle. Vaccine 2020; 38:2519-2526. [PMID: 32037222 DOI: 10.1016/j.vaccine.2020.01.089] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 12/18/2019] [Accepted: 01/29/2020] [Indexed: 12/11/2022]
Abstract
Botulism is a paralytic disease caused by the intoxication of neurotoxins produced by Clostridium botulinum. Among the seven immunologically distinct serotypes of neurotoxins (BoNTs A - G), serotypes C and D, or a chimeric fusion termed C/D or D/C, are responsible for animal botulism. The most effective way to prevent botulism in cattle is through vaccination; however, the commercially available vaccines produced by detoxification of native neurotoxins are time-consuming and hazardous. To overcome these drawbacks, a non-toxic recombinant vaccine was developed as an alternative. In this study, the recombinant protein vaccine was produced using an Escherichia coli cell-based system. The formaldehyde-inactivated E. coli is able to induce 7.45 ± 1.77 and 6.6 ± 1.28 IU/mL neutralizing mean titers against BoNTs C and D in cattle, respectively, determined by mouse neutralization bioassay, and was deemed protective by the Brazilian legislation. Moreover, when the levels of anti-BoNT/C and D were compared with those achieved by the recombinant purified vaccines, no significant statistical difference was observed. Cattle vaccinated with the commercial vaccine developed 1.33 and 3.33 IU/mL neutralizing mean titers against BoNT serotypes C and D, respectively. To the best of our knowledge, this study is the first report on recombinant E. coli bacterin vaccine against botulism. The vaccine was safe and effective in generating protective antibodies and, thus, represents an industry-friendly alternative for the prevention of cattle botulism.
Collapse
Affiliation(s)
- Clóvis Moreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Marcos R A Ferreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Paula F Finger
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Carolina G Magalhães
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Carlos E P Cunha
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Rafael R Rodrigues
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Denis Y Otaka
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará, CEP 68740-970, Brazil
| | - Cleideanny C Galvão
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará, CEP 68740-970, Brazil
| | - Felipe M Salvarani
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará, CEP 68740-970, Brazil
| | - Ângela N Moreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Fabricio R Conceição
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil.
| |
Collapse
|